Teva Pharmaceutical Industries Limited (TEVA) News
Track canonical SquawkNews coverage tagged to TEVA, Teva Pharmaceutical Industries Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ) stock is trading higher on Wednesday after the company reported second-quarter earnings and a direct U.S. listing. • Teva Pharmaceutical Indus shares are powering higher.
EARNINGS | Jul 29, 2026, 05:57 PM UTC
H
Teva CEO: Emalex Acquisition to be Accretive Very Fast
Teva expects Emalex acquisition to be accretive soon
MNA | Jul 29, 2026, 01:45 PM UTC
L
TEVA +7.1% after Co forecasts 2026 profit above estimates
TEVA +7.1% after Co forecasts 2026 profit above estimates
EQUITY | Jul 29, 2026, 01:42 PM UTC
M
Teva CEO: Hopes To Launch Ecopipam In 2027
Teva plans ecopipam launch
EQUITY | Jul 29, 2026, 12:11 PM UTC
L
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16
Teva Pharmaceutical Indus (NYSE: TEVA ) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.500 billion-$16.85
EARNINGS | Jul 29, 2026, 11:20 AM UTC
L
Teva posts Q2 sales $4.1B, EPS $0.02
Teva reports Q2 sales and EPS
EARNINGS | Jul 29, 2026, 11:10 AM UTC
L
TEVA +4.2% premarket after Co forecasts 2026 profit above estimates
TEVA +4.2% premarket after Co forecasts 2026 profit above estimates
EQUITY | Jul 29, 2026, 11:08 AM UTC
M
Teva Replaces ADS Program
Teva replaces ADS program with direct listing
EQUITY | Jul 29, 2026, 11:08 AM UTC
L
TEVA Teva RESULTS: Q2, Q2 Net Income $-575M, Q2 REV $4.142B, Q2 ADJ EPS $0.02, Teva Earnings Notes:, Outlook FY REV $16,500-16.850B, Outlook
TEVA Teva RESULTS: Q2, Q2 Net Income $-575M, Q2 REV $4.142B, Q2 ADJ EPS $0.02, Teva Earnings Notes:, Outlook FY REV $16,500-16.850B, Outlook FY ADJ EPS $1.91-2.11
EARNINGS | Jul 29, 2026, 11:03 AM UTC
H
TEVA raises guidance
TEVA raises guidance
EQUITY | Jul 29, 2026, 11:01 AM UTC
L
TEVA - Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot t
TEVA - Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
EARNINGS | Jul 29, 2026, 11:00 AM UTC
H
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.8%, GD +/-3.7%, TEVA +/-6.5%, JCI +/-7.8%, CTSH +/-11.7%, ODFL +/-8.3%, ETR +/-4
EARNINGS | Jul 28, 2026, 06:05 PM UTC
L
TEVA Earnings pre-market tomorrow: qtr EPS est $0.29 (high $0.66/low $0.04), 30-day avg EPS revision -87.4% (0 analyst(s) revised up, 3 down
TEVA Earnings pre-market tomorrow: qtr EPS est $0.29 (high $0.66/low $0.04), 30-day avg EPS revision -87.4% (0 analyst(s) revised up, 3 down), qtr revs est $4.03B; FY EPS est $2.09, FY revs est $16.55B; short interest 2.
EARNINGS | Jul 28, 2026, 04:12 PM UTC
L
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
EQUITY | Jul 22, 2026, 12:51 PM UTC
L
TEVA Reiterate Overweight after KOL call W leading dermatologist @ Piper
TEVA Reiterate Overweight after KOL call W leading dermatologist @ Piper
EQUITY | Jul 20, 2026, 12:37 PM UTC
H
Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’
In a recent interview, legendary investor Bill Ackman was asked about why he was bullish on the economy of Israel. The question comes with Ackman owning around a 5% stake in the Tel Aviv Stock Exchange. • Teva Pharmaceut
MNA | Jul 08, 2026, 10:47 PM UTC
H
Teva call volume above normal and directionally bullish
Bullish option flow detected in Teva with 23,720 calls trading, 2x expected, and implied vol increasing over 4 points to 51.86%. Jul-26 35.5 calls and Aug-26 40 calls are the most active options, with total volume in tho
EQUITY | Jul 06, 2026, 07:45 PM UTC
L
TEVA Releases Q2 Aide Memoire
Teva releases Q2 2026 aide memoire
EARNINGS | Jun 18, 2026, 09:00 PM UTC